Celldex Therapeutics (NASDAQ: CLDX) +29% - Late Friday, the company announced interim results of its Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM), showing gains in survival rates.
Amicus Therapeutics (NASDAQ: FOLD) +15% - Shares are up sharply Monday as the company announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat") for Fabry disease.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Baker Hughes Inc. (NYSE: BHI) +12% - On Monday, Halliburton confirmed it will buy Baker Hughes for $34.6 billion.
Exterran Holdings Inc. (NYSE: EXH) +7% - On Monday the company’s board of directors announced plans to pursue a plan to separate the company's international contract operations, international aftermarket services and global fabrication businesses into a stand alone, publicly traded company (SpinCo), resulting in two independent companies.
Allergan Inc. (NYSE: AGN) + 6% - Actavis Plc announced Monday that they will acquire Allergan for $66 billion or $129 per share.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.